Advertisement

Topics

Priority review and breakthrough status for AZ’ acalabrutinib

05:02 EDT 2 Aug 2017 | PharmaTimes

AstraZeneca and group member Acerta Pharma say acalabrutinib is being given a priority review by the US Food and Drug Administration for mantle cell lymphoma (MCL), hot on the heels of it having been assigned a breakthrough designation by the regulator.

Original Article: Priority review and breakthrough status for AZ’ acalabrutinib

NEXT ARTICLE

More From BioPortfolio on "Priority review and breakthrough status for AZ’ acalabrutinib"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...